Javier Fernández-Calvo

Author PubWeight™ 9.64^‹?›

Top papers

Rank	Title	Journal	Year	PubWeight™‹?›
1	High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA.	Blood	2005	1.97
2	Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma: a tool for comparing the efficacy of different treatment strategies and predicting outcome.	Blood	2002	1.21
3	Minimal residual disease in adolescent (older than 14 years) and adult acute lymphoblastic leukemias: early immunophenotypic evaluation has high clinical value.	Blood	2003	1.06
4	Methylation is an inactivating mechanism of the p16 gene in multiple myeloma associated with high plasma cell proliferation and short survival.	Br J Haematol	2002	1.05
5	Pamidronate induces bone formation in patients with smouldering or indolent myeloma, with no significant anti-tumour effect.	Br J Haematol	2002	0.97
6	Fluorescence in situ hybridization analysis of aneuploidization patterns in monoclonal gammopathy of undetermined significance versus multiple myeloma and plasma cell leukemia.	Cancer	2003	0.93
7	Prognostic value of karyotypic analysis in children and adults with high-risk acute lymphoblastic leukemia included in the PETHEMA ALL-93 trial.	Haematologica	2002	0.88
8	FLT3-activating mutations are associated with poor prognostic features in AML at diagnosis but they are not an independent prognostic factor.	Hematol J	2004	0.86
9	The value of fluorescence in situ hybridization for the detection of 11q in multiple myeloma.	Haematologica	2004	0.84
10	[Prognostic influence of immunological subtypes of T-cell acute lymphoblastic leukemia. Study of 81 patients].	Med Clin (Barc)	2006	0.75